Literature DB >> 26373896

Advagraf(®) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts.

Sophie Caillard1, Bruno Moulin1, Fanny Buron2, Christophe Mariat3, Vincent Audard4, Philippe Grimbert4, Pierre Marquet5.   

Abstract

The efficacy and safety of tacrolimus twice-a-day (BID) and once-a-day (QD) formulations are similar. However, the available information regarding the initiation and management of tacrolimus QD is sparse and practical information is lacking. A panel of French experts extensively reviewed the available literature on tacrolimus pharmacokinetics, clinical efficacy, and safety in kidney transplantation and, based on their own day-to-day experience, provided the practitioners with practical guidelines for the daily use and management of tacrolimus QD in de novo initiation or early conversion.
© 2015 Steunstichting ESOT.

Entities:  

Keywords:  clinical practice; extended release tacrolimus; immunosuppression; kidney transplant; therapeutic drug monitoring

Mesh：

Substances：

Year:  2015        PMID： 26373896     DOI： 10.1111/tri.12674

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


  7 in total

1.  Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study.

Authors:  Sayamon Sukkha; Busba Chindavijak; Preecha Montakantikul; Atiporn Ingsathit; Wichit Nosoongnoen; Vasant Sumethkul
Journal:  Int J Clin Pharm       Date:  2017-11-03

2.  Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients.

Authors:  Jong Man Kim; Pyoung-Jae Park; Geun Hong; Dong Jin Joo; Kwan Woo Kim; Je Ho Ryu; Young Seok Han; Jai Young Cho; Gi-Won Song; Bong-Wan Kim; Dong-Sik Kim; Seong Hoon Kim; Sang Tae Choi; Young Kyoung You; Kyung-Suk Suh; Yang-Won Na; Koo Jeong Kang; Jae-Won Joh
Journal:  Korean J Transplant       Date:  2021-09-30

3.  Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.

Authors:  Nassim Kamar; Elisabeth Cassuto; Giovanni Piotti; Mirco Govoni; Giorgia Ciurlia; Silvia Geraci; Gianluigi Poli; Gabriele Nicolini; Christophe Mariat; Marie Essig; Paolo Malvezzi; Yannick Le Meur; Valerie Garrigue; Arnaud Del Bello; Lionel Rostaing
Journal:  Adv Ther       Date:  2018-12-14       Impact factor: 3.845

4.  A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study.

Authors:  Valérie Moal; Philippe Grimbert; Adrien Beauvais; Laurence Dubel; Yann Le Meur
Journal:  Ann Transplant       Date:  2019-09-03       Impact factor: 1.530

5.  Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.

Authors:  Bing Ho; Hardik Bhagat; Jason J Schwartz; Kofi Atiemo; Amna Daud; Raymond Kang; Samantha E Montag; Lihui Zhao; Edward Lee; Anton I Skaro; Daniela P Ladner
Journal:  Adv Ther       Date:  2019-04-02       Impact factor: 3.845

6.  Flat Pattern Peaks of Tacrolimus Absorption and Associated Pharmacogenomic Variants in Kidney Transplantation Recipients.

Authors:  Suh Min Kim; Younggyun Lim; Sangil Min; Byung-Joo Min; Myung-Eui Seo; Kye Hwa Lee; Ju Han Kim; Jongwon Ha
Journal:  J Korean Med Sci       Date:  2022-02-07       Impact factor: 2.153

7.  A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.

Authors:  S Tremblay; V Nigro; J Weinberg; E S Woodle; R R Alloway
Journal:  Am J Transplant       Date:  2016-08-02       Impact factor: 8.086
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.